{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:55Z","timestamp":1790898955572,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T00:00:00Z","timestamp":1499126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00280-017-3379-5","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T08:51:10Z","timestamp":1499158270000},"page":"653-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Litaty C.","family":"Mbatchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Gassiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pourquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejando","family":"Goberna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lumbroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"issue":"8","key":"3379_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32(8):760\u2013767. doi: 10.1200\/JCO.2013.50.3961","journal-title":"J Clin Oncol"},{"issue":"3","key":"3379_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","volume":"2","author":"S Huang","year":"2003","unstructured":"Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2(3):222\u2013232","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"3379_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","volume":"23","author":"JM Barbarino","year":"2013","unstructured":"Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563\u2013585. doi: 10.1097\/FPC.0b013e328364db84","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"3379_CR4","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1124\/dmd.107.014746","volume":"35","author":"P Cai","year":"2007","unstructured":"Cai P, Tsao R, Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35(9):1554\u20131563. doi: 10.1124\/dmd.107.014746","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3379_CR5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-3565(24)37526-3","volume":"285","author":"A Lampen","year":"1998","unstructured":"Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U (1998) Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285(3):1104\u20131112","journal-title":"J Pharmacol Exp Ther"},{"key":"3379_CR6","unstructured":"FDA temsirolimus access data. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022088s000_PharmR.pdf . Accessed March 2017"},{"key":"3379_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fgene.2013.00012","volume":"4","author":"K Klein","year":"2013","unstructured":"Klein K, Zanger UM (2013) Pharmacogenomics of Cytochrome P450 3A4: recent progress toward the \u201cmissing heritability\u201d problem. Front Genet 4:12. doi: 10.3389\/fgene.2013.00012","journal-title":"Front Genet"},{"issue":"3","key":"3379_CR8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12659\/AOT.883456","volume":"17","author":"D \u017bochowska","year":"2012","unstructured":"\u017bochowska D, Wyzga\u0142 J, P\u0105czek L (2012) Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transpl 17(3):36\u201344","journal-title":"Ann Transpl"},{"issue":"1","key":"3379_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19\u201324. doi: 10.1002\/cpt.113","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3379_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75(1):13\u201333. doi: 10.1016\/j.clpt.2003.09.012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"3379_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 54(7):709\u2013735. doi: 10.1007\/s40262-015-0267-1","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3379_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","volume":"83","author":"Y Chen","year":"2012","unstructured":"Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83(8):1112\u20131126. doi: 10.1016\/j.bcp.2012.01.030","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"3379_CR13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","volume":"62","author":"AH Tolson","year":"2010","unstructured":"Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62(13):1238\u20131249. doi: 10.1016\/j.addr.2010.08.006","journal-title":"Adv Drug Deliv Rev"},{"issue":"21","key":"3379_CR14","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","volume":"95","author":"G Bertilsson","year":"1998","unstructured":"Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-B\u00e4ckman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95(21):12208\u201312213","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"3379_CR15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1389200054633880","volume":"6","author":"J Lamba","year":"2005","unstructured":"Lamba J, Lamba V, Schuetz E (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6(4):369\u2013383","journal-title":"Curr Drug Metab"},{"issue":"12","key":"3379_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","volume":"48","author":"K Benkali","year":"2009","unstructured":"Benkali K, Pr\u00e9maud A, Picard N, R\u00e9rolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48(12):805\u2013816. doi: 10.2165\/11318080-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"3379_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchromb.2013.01.017","volume":"921\u2013922","author":"A Navarrete","year":"2013","unstructured":"Navarrete A, Mart\u00ednez-Alc\u00e1zar MP, Dur\u00e1n I, Calvo E, Valenzuela B, Barbas C, Garc\u00eda A (2013) Simultaneous online SPE-HPLC-MS\/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 921\u2013922:35\u201342. doi: 10.1016\/j.jchromb.2013.01.017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"3379_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clpt.2004.08.025","volume":"77","author":"JP Boni","year":"2005","unstructured":"Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77(1):76\u201389. doi: 10.1016\/j.clpt.2004.08.025","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3379_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1399-3046.2012.01751.x","volume":"16","author":"M Ferraresso","year":"2012","unstructured":"Ferraresso M, Turolo S, Belinghieri M, Tirelli AS, Grillo P, Groppali E, Edefonti A, Ghio L (2012) The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr Transpl 16(6):658\u2013663. doi: 10.1111\/j.1399-3046.2012.01751.x","journal-title":"Pediatr Transpl"},{"issue":"12","key":"3379_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1373\/clinchem.2013.204990","volume":"59","author":"JB Woillard","year":"2013","unstructured":"Woillard JB, Kamar N, Coste S, Rostaing L, Marquet P, Picard N (2013) Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. Clin Chem 59(12):1761\u20131769. doi: 10.1373\/clinchem.2013.204990","journal-title":"Clin Chem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3379-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3379-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:20:11Z","timestamp":1750479611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3379-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3379-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,4]]}}}